ZYBERNO
Stock Report
Updated Aug 30, 2026

ZURA BIO LIMITED (ZURA)

Healthcare • NASDAQ

$5.72

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
18.0/100
POOR BUSINESS
ZURA BIO LIMITED (ZURA) scores 18/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-54.8%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.08x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-841.2%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

ZURA BIO LIMITED (ZURA) stock report — Zyberno Score 18/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, ZURA generated -$72.73M in Owner Earnings. Capital was deployed as follows: $77.00K invested in capital expenditures. Reinvestment rate: -0.1%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:5.72
Market Cap:$725.32M

Valuation Multiples (2)

P/B Ratio:3.68x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$536.50M

Price Action & Momentum (3)

Momentum Percentile:99 / 100
% of 52-Week High:76.9%
B. Profitability Assessment

Return Metrics (5)

ROA:-49.0%
Reinvestment Rate:-0.1%
Fundamental Growth Rate (g):0.8%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$19.55
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-153.4%
Latest Earnings Filed:2026-08-11
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:12.90x
Quick Ratio:12.90x
Cash Ratio:12.57x

Leverage Analysis (3)

Debt To Equity Ttm:0.08x
Debt-to-Equity Ratio:0.08x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:194,182,000.00
Cash And Cash Equivalents:205,134,000.00
Long Term Debt:$0.00
Net Debt:-$188.82M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$92.75M

Bottom Line Performance (3)

-$85.74M
Income Before Tax:-$85.82M
Ebitda Ttm:-92,694,000.00

Operating Expenses (5)

Operating Expenses:92,750,000.00
R And D Expense:58,356,000.00
Sga Expense:34,394,000.00
Income Tax Expense:-$81.00K
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$213.40M
Current Assets:$210.50M
Ppe Net:149,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:16,318,000.00
Current Liabilities:16,318,000.00
Long Term Debt:$0.00
Short Term Debt:$16.32M

Equity & Capital (3)

Equity:$197.09M
Retained Earnings:-$275.07M
Common Stock:300,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:16,318,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:4,457,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$72.68M-$72.75M

Investment Activities (2)

Investing Cash Flow:-$13.00K
Capital Expenditures Ttm:77,000.00

Financing Activities (3)

Financing Cash Flow:$135.12M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:56,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.13
-$1.13
Earnings Per Share Ttm:-$0.68

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$0.51

Book Value & Capital (2)

Book Value Per Share:$1.55
Cash Per Share:1.62

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$72.73M

Damodaran Growth Analysis (2)

Reinvestment Rate:-0.1%
Fundamental Growth Rate (g):0.8%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):54.2%
C. Company Profile & Context

Corporate Information (6)

Symbol:ZURA
Company Name:ZURA BIO LIMITED
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:126.80M
Shares Outstanding Basic:126.80M
Shares Outstanding Diluted:126.80M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-30 21:48:19 UTC
Data Timestamp:2026-08-18T00:42:55.223169
Scroll to Top